tradingkey.logo

Vir Biotechnology soars on Q4 results beat, Astellas collaboration

ReutersFeb 24, 2026 10:42 AM

Shares of drug developer Vir Biotechnology VIR.O rise 65.2% at $12.28 premarket

Co posts Q4 revenue of $64.1 mln, beating analyst est. of $23.1 mln; posts Q4 loss per share of 31 cents, compared with the consensus of loss of 49 cents - data compiled by LSEG

Co highlights its agreement with Norgine and lower R&D expenses due to restructuring initiatives

Co also plans to develop and commercialize its prostate cancer experimental drug with Japan's Astellas 4503.T

As of last close, VIR stock up 23.2% YTD, following a 17.8% decline in 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI